Clinical Trial Detail

NCT ID NCT03107988
Title Study of Lorlatinib (PF-06463922)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors New Approaches to Neuroblastoma Therapy Consortium
Indications

neuroblastoma

Therapies

Cyclophosphamide + Lorlatinib + Topotecan

Lorlatinib

Age Groups: child adult senior

Additional content available in CKB BOOST